Potential Benefit of Uric Acid for Thrombolytic Therapy in Acute Ischemic Stroke
- *Corresponding Author:
- Kiyoshi Kikuchi
Division of Brain Science
Department of Physiology
Kurume University School of Medicine
67 Asahi-machi, Kurume 830-0011, Japan
E-mail: [email protected]
Received Date: February 11, 2016; Accepted Date: February 20, 2016; Published Date: February 23, 2016
Citation: Kikuchi K, Morioka M, Murai Y, Tanaka E (2016) Potential Benefit of Uric Acid for Thrombolytic Therapy in Acute Ischemic Stroke. Biochem Anal Biochem 5:250. doi:10.4172/2161-1009.1000250
Copyright: © 2016 Kikuchi K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Alteplase (recombinant tissue plasminogen activator) is the only licensed drug for acute ischemic stroke (AIS) treatment, but only 3–5% of patients with AIS receive thrombolytic treatment using alteplase. Further breakthroughs are needed for thrombolysis in AIS because thrombolytic therapy does not benefit all patients equally. Alteplase administration can induce intracerebral hemorrhage or a low rate of recanalization for occlusion of major cerebral arteries (e.g., internal carotid artery). Recently, the effect of alteplase–uric acid (UA) combination therapy was demonstrated in a clinical trial of AIS patients. UA administration resulted in a significant improvement in functional outcome in patients with hyperglycemia, female patients, and patients who had suffered a moderate stroke. Oxidative stress and antioxidant properties would be differ in each AIS patients after reperfusion. Therefore, the optimal dose of UA may vary according to sex, age, body weight, ethnicity and medical history (e.g., diabetes mellitus). Hence, various study arms may be needed in future, large clinical trials. In the future, if levels of oxidative stress or antioxidant properties can be determined rapidly in AIS patients before treatment, the optimal dose of antioxidant may be ascertained.